What type of drug does Sotagliflozin belong to?

Sotagliflozin belongs to a class of drugs called SGLT1/2 inhibitors. SGLT refers to the sodium glucose co-transporter, and Sotagliflozin has the property of inhibiting both SGLT1 and SGLT2 two isoforms.

SGLT1 and SGLT2 are two glucose transporters found in the human kidney and intestine. They play a key role in regulating blood sugar levels. SGLT2 is mainly distributed in the renal tubules and is responsible for the reabsorption of glucose in urine, while SGLT1 is mainly present in the small intestine and is involved in the absorption of glucose from food.

Sogliflozin achieves dual hypoglycemic effects by simultaneously inhibiting SGLT1 and SGLT2. In the kidneys, it reduces the reabsorption of glucose from the urine, causing more glucose to be excreted and lowering blood sugar levels. In the intestine, soxgliflozin slows the absorption of glucose from food and helps control post-meal blood sugar levels.

The dual effects of sogliflozin make it an innovative oral hypoglycemic drug suitable for the treatment of patients with type 2 diabetes. It is often used as an adjunctive treatment, in conjunction with diet control and exercise, to comprehensively manage a patient's blood sugar levels.

The research and application of this type ofSGLT1/2 inhibitors represents progress in the field of diabetes treatment and provides patients with more treatment options. However, when using sogliflozin or other SGLT1/2 inhibitors, patients need to closely follow their doctor's recommendations, monitor blood sugar levels, be aware of possible side effects, and undergo regular medical examinations to ensure safe and effective treatment.